Latigo raises $150m for non-opioid painkiller push

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million for drugs that it hopes will challenge Vertex Pharma's first-in-class Journavx.